EXC vs LAB · P/E 17, rev $23.03B vs rev $174.4M
Exelon Corporation (EXC) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
Exelon Corporation (EXC) is a utilities - regulated electric company listed on NASDAQ.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported EXC revenue for 2024-12-31 was $23.03B. Net income was $2.46B. Revenue was up 6.0% from 2023-12-31 to 2024-12-31. EXC currently screens at market cap $47.33B and trailing P/E 16.8.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
EXC currently screens at market cap $47.33B and trailing P/E 16.8. LAB currently screens at market cap $317.1M.
Not investment advice. Open the EXC and LAB stock pages for the full models.
Not investment advice.